Pharming Group Nv Stock Today
| PHAR Stock | USD 8.80 0.15 1.68% |
PerformanceWeak
| Odds Of DistressAverage
|
Pharming Group is selling at 8.80 as of the 19th of March 2025; that is 1.68 percent down since the beginning of the trading day. The stock's lowest day price was 8.62. Pharming Group has 53 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of December 2020 | Category Healthcare | Classification Health Care |
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. Pharming Group N.V. The company has 67.84 M outstanding shares of which 5.26 K shares are at this time shorted by private and institutional investors with about 0.5 trading days to cover. More on Pharming Group NV
Moving against Pharming Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Pharming Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Fabrice Chouraqui | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Pharco SA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPharming Group can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pharming Group's financial leverage. It provides some insight into what part of Pharming Group's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharming Group NV (PHAR) is traded on NASDAQ Exchange in USA. It is located in Darwinweg 24, Leiden, Netherlands, 2333 CR and employs 14 people. Pharming Group is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 596.95 M. Pharming Group NV conducts business under Biotechnology sector and is part of Health Care industry. The entity has 67.84 M outstanding shares of which 5.26 K shares are at this time shorted by private and institutional investors with about 0.5 trading days to cover.
Pharming Group NV currently holds about 189.96 M in cash with (17.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.91.
Check Pharming Group Probability Of Bankruptcy
Ownership AllocationPharming Group owns a total of 67.84 Million outstanding shares. Roughly 99.89 pct. of Pharming Group outstanding shares are held by general public with 0.11 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Pharming Ownership Details
Pharming Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Silverberg Bernstein Capital Management Llc | 2024-12-31 | 48 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.6 K | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 483 | |
| Ubs Group Ag | 2024-12-31 | 10.0 | |
| Blackrock Inc | 2024-12-31 | 0.0 |
Pharming Group Historical Income Statement
Pharming Stock Against Markets
Pharming Group Corporate Management
| Bruno Giannetti | Consultant | Profile | |
| Susanne Embleton | Investor Manager | Profile | |
| Jeroen Wakkerman | Chief Officer | Profile | |
| Stephen Toor | Chief Americas | Profile | |
| MBA MD | CEO Pres | Profile | |
| Daniela Hanovana | Chief Officer | Profile |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.